肾移植后恶性肿瘤相关危险因素：来自国际癌症-肾脏网络的一篇文章。

Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network.

作者信息

Sprangers Ben, Nair Vinay, Launay-Vacher Vincent, Riella Leonardo V, Jhaveri Kenar D

机构信息

Department of Microbiology and Immunology, KU Leuven and Division of Nephrology, University Hospitals Leuven, Leuven, Belgium.

Department of Microbiology and Immunology, KU Leuven and Laboratory of Experimental Transplantation, University Hospitals Leuven, Leuven, Belgium.

出版信息

Clin Kidney J. 2018 Jun;11(3):315-329. doi: 10.1093/ckj/sfx122. Epub 2017 Oct 27.

DOI:10.1093/ckj/sfx122

PMID:29942495

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6007332/

Abstract

In kidney transplant recipients, cancer is one of the leading causes of death with a functioning graft beyond the first year of kidney transplantation, and malignancies account for 8-10% of all deaths in the USA (2.6 deaths/1000 patient-years) and exceed 30% of deaths in Australia (5/1000 patient-years) in kidney transplant recipients. Patient-, transplant- and medication-related factors contribute to the increased cancer risk following kidney transplantation. While it is well established that the overall immunosuppressive dose is associated with an increased risk for cancer following transplantation, the contributive effect of different immunosuppressive agents is not well established. In this review we will discuss the different risk factors for malignancies after kidney transplantation.

摘要

在肾移植受者中，癌症是肾移植术后第一年存活移植物相关的主要死亡原因之一，在美国，恶性肿瘤占所有死亡病例的8-10%（每1000患者年有2.6例死亡），在澳大利亚肾移植受者中，恶性肿瘤导致的死亡超过30%（每1000患者年有5例死亡）。患者、移植及药物相关因素导致肾移植后癌症风险增加。虽然已明确总体免疫抑制剂量与移植后癌症风险增加有关，但不同免疫抑制剂的具体作用尚不明确。在本综述中，我们将讨论肾移植后发生恶性肿瘤的不同危险因素。